Treatment to prevent transmission of HIV-1

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Cohen, Myron S ^a   Gay, Cynthia L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, INFECTIOUS; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951822950     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651478     Document Type: Review

References (115)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report. Vol.2007. http://www.who.int/hiv/mediacentre/universal-access-progress-report-en.pdf. Accessed 21 December 2007.
2. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
3. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séro positives ne souffrant d'aucune autre MST et suivant un traitment antiretroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des médecins suisses 2008; 89.
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
5. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009;301:2380-2382.
6. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008; 118:1244-1254. (Pubitemid 351500417)
7. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-929.
8. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17: 901-910. (Pubitemid 32881333)
9. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283. (Pubitemid 34208536)
10. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
11. Trask SA, Derdeyn CA, Fideli U, et al. Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol 2002; 76:397-405. (Pubitemid 33139024)
12. Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35:55-60. (Pubitemid 351619353)
13. Chakraborty H, Helms RW, Sen PK, Cohen MS. Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. Stat Med 2003;22:1457-1464. (Pubitemid 36575595)
14. Vergidis PI, Falagas ME, Hamer DH. Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infect Dis Clin North Am 2009; 23:295-308.
15. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
16. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
17. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007;21:501-507. (Pubitemid 46263261)
18. Cu-Uvin S, Caliendo A, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14: 415-1121
19. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169-2176. (Pubitemid 37338890)
20. Nagot N, Ouedraogo A, Weiss HA, et al. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect 2008; 84:167-170. (Pubitemid 351871485)
21. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003; 17:455-480.
22. Brambilla D, Reichelderfer PS, Bremer JW, et al. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999; 13: 2269-2279.
23. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42:584-587. (Pubitemid 44162427)
24. Al-Harthi L, Kovacs A, Coombs RW, et al. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS 2001; 15:1535-1543. (Pubitemid 32744601)
25. Xu C, Politch JA, Tucker L, Mayer KH, Seage GR 3rd, Anderson DJ. Factors associated with increased levels of human immunodeficiency virus type 1 DNA in semen. J Infect Dis 1997; 176:941-947. (Pubitemid 27411036)
26. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997;349:1868-1873.
27. Sheth PM, Shahabi K, Rebbapragada A, et al. HIV viral shedding in semen: lack of correlation with systemic virus-specific CD8 responses. AIDS 2004; 18:2202-2205. (Pubitemid 39463688)
28. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000; 14:117-121. (Pubitemid 30116436)
29. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-1809. (Pubitemid 29005784)
30. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238-243. (Pubitemid 36070370)
31. Sheth P, Kovacs C, Kemal K, et al. Persistent HIV RNA shedding in semen despite effective ART. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Toronto). 2009. Abstract 50.
32. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F189.
33. Si-Mohamed A, Kazatchkine M, Heard I, et al. Selection of drugresistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. JID 2000;182:112-122. (Pubitemid 30497795)
34. Mayer KH, Boswell S, Goldstein R, et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999;28:1252-1259. (Pubitemid 29272799)
35. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21:1899-1907.
36. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42. (Pubitemid 39490046)
37. Sadiq ST, Taylor S, Kaye S, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16:219-225. (Pubitemid 34118569)
38. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799. (Pubitemid 46294611)
39. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998; 177: 320-330. (Pubitemid 28063755)
40. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-1601. (Pubitemid 33101909)
41. Andreoletti L, Skrabal K, Perrin V, et al. Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral-treatment-naive clade a human immunodeficiency virus type 1-infected women. J Clin Microbiol 2007; 45: 1838-1842. (Pubitemid 46933915)
42. Philpott S, Burger H, Tsoukas C, et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol 2005; 79:353-363. (Pubitemid 39648389)
43. De Pasquale M. HIV-1 replicates locally in sub-compartments of female genital tract. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Toronto). 2009. Abstract 280b.
44. Lampinen TM, Critchlow CW, Kuypers JM, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000; 14:F69-F75.
45. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-1976. (Pubitemid 24276382)
46. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40:96-101. (Pubitemid 41233212)
47. Were WA, Mermin JH, Wamai N, et al. Undiagnosed HIV infection and couple HIV discordance among household members of HIVinfected people receiving antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 2006;43:91-95. (Pubitemid 44306494)
48. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Toronto). 2009. Abstract 52bLB.
49. Powers KA, Poole C, Pettifor AE and Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553-563.
50. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
51. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88. (Pubitemid 38402321)
52. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
53. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378. (Pubitemid 32163823)
54. Stolte IG, Dukers NH, de Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 2001;77:184-186. (Pubitemid 32595739)
55. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394.
56. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
57. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-1197.
58. National Institute of Allergy and Infectious Diseases. Starting antiretroviral therapy earlier yields better clinical outcomes. National Institute of Health News, 2009. http://www.nih.gov/news/health/ jun2009/niaid-08a.htm. Accessed 26 June 2009.
59. HIV Prevention Trials Network, http://www.hptn.org. Accessed 25 June 2009.
60. Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest 2004;113:937-945. (Pubitemid 38544111)
61. Fidler S, Fox J, Porter K, Weber J. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 2008;21:4-10.
62. Kalichman SC, Eaton L, Cain D, Cherry C, Pope H, Kalichman M. HIV treatment beliefs and sexual transmission risk behaviors among HIV positive men and women. J Behav Med 2006;29:401-1110
63. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236. (Pubitemid 38918000)
64. Ostrow DE, Fox KJ, Chmiel JS, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002; 16: 775-780.
65. Kelly JA, Hoffman RG, Rompa D, Gray M. Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex. AIDS 1998; 12:F91-F95. (Pubitemid 28302411)
66. Kalichman SC. Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Am J Prev Med 1998; 15:120-127.
67. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis 2004;38:1167-1174. (Pubitemid 38951266)
68. Ostrow DG, Silverberg MJ, Cook RL, et al. Prospective study of attitudinal and relationship predictors of sexual risk in the multicenter AIDS cohort study. AIDS Behav 2008; 12:127-138.
69. Cox J, Beauchemin J, Allard R. HIV status of sexual partners is more important than antiretroviral treatment related perceptions for risk taking by HIV positive MSM in Montreal, Canada. Sex Transm Infect 2004;80:518-523. (Pubitemid 39627260)
70. Rawstorne P, Fogarty A, Crawford J, et al. Differences between HIVpositive gay men who "frequently," "sometimes" or "never" engage in unprotected anal intercourse with serononconcordant casual partners: Positive Health Cohort, Australia. AIDS Care 2007; 19:514-522.
71. Remien RH, Halkitis PN, O'Leary A, Wolitski RJ, Gomez CA. Risk perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy. AIDS Behav 2005;9:167-176. (Pubitemid 40884219)
72. Wilson TE, Feldman J, Vega MY, et al. Acquisition of new sexual partners among women with HIV infection: patterns of disclosure and sexual behavior within new partnerships. AIDS Educ Prev 2007;19:151-159. (Pubitemid 46631754)
73. Stolte IG, de Wit JB, van Eeden A, Coutinho RA, Dukers NH. Perceived viral load, but not actual HIV-1-RNA load, is associated with sexual risk behaviour among HIV-infected homosexual men. AIDS 2004;18:1943-1949.
74. Van de Ven P, Mao L, Fogarty A, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19:179-184. (Pubitemid 40409536)
75. Vanable PA, Ostrow DG and McKirnan DJ. Viral load and HIV treatment attitudes as correlates of sexual risk behavior among HIV-positive gay men. J Psychosom Res 2003; 54:263-269.
76. 76. Kozal MJ, Amico KR, Chiarella J, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004; 18:2185-2189. (Pubitemid 39463684)
77. Diamond C, Richardson JL, Milam J, et al. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr 2005; 39: 211-218. (Pubitemid 40741121)
78. Kennedy C, O'Reilly K, Medley A and Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007; 19:707-720. (Pubitemid 46944272)
79. Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'lvoire. AIDS 2003; 17(Suppl 3):S69-S77.
80. Bateganya M, Colfax G, Shafer LA, et al. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS 2005; 19: 760-768. (Pubitemid 41705172)
81. Kaida A, Gray G, Bastos Fl, et al. The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care 2008;20:21-25. (Pubitemid 351264535)
82. Sarna A, Luchters SM, Geibel S, et al. Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya. lnt J STD AIDS 2008; 19:85-89.
83. Luchters S, Sarna A, Geibel S, et al. Safer sexual behaviors after 12 months of antiretroviral treatment in Mombasa, Kenya: a prospective cohort. AIDS Patient Care STDS 2008; 22:587-594.
84. Eisele TP, Mathews C, Chopra M, et al. High levels of risk behavior among people living with HIV Initiating and waiting to start antiretroviral therapy in Cape Town South Africa. AIDS Behav 2008; 12: 570-577. (Pubitemid 351873634)
85. Diabate S, Alary M and Koffi CK. Short-term increase in unsafe sexual behaviour after initiation of HAART in Cote d'Ivoire. AIDS 2008; 22:154-156. (Pubitemid 350294892)
86. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLOS Medicine 2006; 3: el24.
87. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14. (Pubitemid 40111013)
88. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. (Pubitemid 32592362)
89. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67. (Pubitemid 351920290)
90. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008;372:314-320. (Pubitemid 352020440)
91. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650-654. (Pubitemid 30070912)
92. Fraser C, Hollingsworth TD, Chapman R, Anderson RM. Quantifying the impact of primary infection on HIV transmission and control. In: Program and abstract of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006. Abstract 162.
93. World Health Organization. Antiretroviral therapy for HIV prevention. Vol.2009. Geneva: World Health Organization, 2009. http:// www.who.int/hiv/ events/artprevention/en/index.html. Accessed 21 December 2009.
94. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
95. Truong HM, Grant RM, McFarland W, et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-2197. (Pubitemid 44684710)
96. Angarano G, Monno L, Appice A, et al. Transmission of zidovudineresistant HIV-1 through heterosexual contacts. AIDS 1994; 8: 1013-1014.
97. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994; 169: 411-1115
98. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175:1502-1506.
99. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-2137.
100. Johnson LF, Lewis DA. The effect of genital tract infections on HIV1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946-959.
101. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20:73-83.
102. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52. (Pubitemid 34043015)
103. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-2119. (Pubitemid 351902179)
104. Celum C, Wald A, Hughes J, et al. Incidence of genital ulcers and HSV+ genital ulcers in trial of HSV-2 suppression to prevent HIV acquisition (HPTN 039). In: Program and abstracts of the XVII International AIDS Conference (Mexico City). 2008. Abstract THAC302.
105. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260-270.
106. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999;43:1817-1826.
107. Pereira AS, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999; 180: 2039-2043.
108. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882. (Pubitemid 29159332)
109. Cohen M, Kaleebu P, Coates T. Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc 2008; 11:4.
110. De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet 2009; 373:7-9.
111. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006; 296:863-865.
112. Donnell D, Kiarie J, Thomas K, et al. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA). 2010. Abstract 136.
113. Das-Douglas M, Chu P, Santos G-M, et al. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA). 2010. Abstract 33.
114. Montaner J, Wood E, Kerr T, et al. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in British Columbia, Canada. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA). 2010. Abstract 88LB.
115. Castel A, Samala R, Griffin A, et al. Monitoring the impact of expanded HIV testing in the District of Columbia using populationbased HIV/AIDS surveillance data. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections (San Frsancisco, CA). 2010. Abstract 34.